Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B

• Published in: International journal of medical sciences Vol. 9; no. 1; pp. 27 - 32
• Main Authors: Kanda, Tatsuo, Shinozaki, Masami, Kamezaki, Hidehiro, Wu, Shuang, Nakamoto, Shingo, Arai, Makoto, Fujiwara, Keiichi, Goto, Nobuaki, Imazeki, Fumio, Yokosuka, Osamu
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher 01.01.2012
• Subjects: Adult; Aged; Alanine Transaminase - analysis; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Disease Progression; DNA, Viral - drug effects; Drug Resistance - genetics; Female; Guanine - administration & dosage; Guanine - analogs & derivatives; Guanine - therapeutic use; Hepatitis B virus - drug effects; Hepatitis B virus - genetics; Hepatitis B, Chronic - drug therapy; Humans; Lamivudine - administration & dosage; Lamivudine - therapeutic use; Male; Middle Aged; Research Paper; Retrospective Studies; Reverse Transcriptase Inhibitors - therapeutic use; acute exacerbation; ALT; entecavir; HBV; lamivudine
• ISSN: 1449-1907; 1449-1907
• DOI: 10.7150/ijms.9.27

Spontaneous acute exacerbation of chronic hepatitis B virus (HBV) infection occasionally occurs in its natural history, sometimes leading rapidly to fatal hepatic failure. We compared the effects of lamivudine (LAM) with those of entecavir (ETV) treatments in acute exacerbation of chronic hepatitis B with 500 IU/L or higher alanine aminotransferase (ALT) levels. Thirty-four patients with acute exacerbation were consecutively treated with LAM /ETV. Their clinical improvements were compared. Among LAM-treated and ETV-treated patients, none showed a reduction of <1 log IU/mL in HBV DNA after 1 or 3 months of treatment. Initial virological response, defined as a reduction of 4 log IU/mL in HBV DNA at 6 months, with LAM and ETV, respectively, was 83.3% and 100%. One LAM patient developed hepatic encephalopathy, but all patients in both groups survived. Twelve months after treatment, 41.6% of 24 LAM group patients switched to another drug or added adefovir to their treatment due to the emergence of LAM-resistant mutants. On the other hand, patients receiving ETV did not need to change drugs. ETV appears to be as effective as LAM in the treatment of patients with acute exacerbation of chronic hepatitis B. Clinicians should carefully start to treat these patients as soon as possible.